USANA (USNA) Falls Following Q3 Warning on Softer Sales

September 16, 2021 4:40 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

USANA Health Sciences, Inc. (NYSE: USNA) shares are trading around 3% lower after-hours on Thursday following the company’s preliminary Q3 results and updated outlook for 2021 which fell shy of expectations.

The Company expects Q3/21 net sales to range between $265 and $270 million (vs. $299 million in Q3/20) and EPS to range between $1.28 and $1.33 (vs. $1.44 in Q3/20). The compares unfavorably to the consensus of $303.24 million and $1.44, respectively.

According to Kevin Guest, CEO and Chairman of the Board of USANA Health Sciences, Q3 sales were softer than expected, mainly due to increased disruptions and lockdowns in several of its markets due to the escalation of the COVID-19 pandemic, which affected the company’s customers and salesforce and, in some cases, the company’s ability to operate and ship products.

The company updated its full 2021-year outlook, now expecting net sales of $1.18 - $1.20 billion (vs. prior $1.24 - $1.28 billion) and EPS of $5.80 - $6.00 (vs. prior $6.15 - $6.50). The full-year consensus is $1.26 billion and $6.35.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Guidance, Hot Guidance, Trader Talk